Results 61 to 70 of about 278,336 (309)

Current Pharmacotherapy of Non-Small Cell Lung Cancer

open access: yes, 2023
Non-small cell lung cancer (NSCLC) is a prevalent form of lung cancer and a significant cause of cancer-related mortality worldwide. It constitutes approximately 80-85% of all lung cancer cases.
Srinivasan, Sankara Narayanan
core  

Mitochondrial Variations in Non-Small Cell Lung Cancer (NSCLC) Survival [PDF]

open access: yes, 2015
Mutations in the mtDNA genome have long been suspected to play an important role in cancer. Although most cancer cells harbor mtDNA mutations, the question of whether such mutations are associated with clinical prognosis of lung cancer remains unclear ...
Yang Zhao   +19 more
core   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

open access: yesMolecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington   +10 more
wiley   +1 more source

Laminin-bound integrin α6β4 promotes non-small cell lung cancer progression via the activation of YAP/TAZ signaling pathway

open access: yesFrontiers in Oncology, 2022
Laminin is an extracellular matrix multidomain trimeric glycoprotein, that has a potential role in tumor progression. Here, we studied the effects of non-small cell lung cancer (NSCLC) cells interaction on laminin and explored the underlying mechanism of
Xiaopeng Zhao   +6 more
doaj   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

A PD-L1 expresszió vizsgálata a nem kissejtes tüdődaganatokban

open access: yes, 2021
Az NSCLC többségét kitevő adenocarcinomák kezelésében a 2000-es években jelentek meg a célzott terápiák. Ennek következtében a molekuláris pathologiai vizsgálatok a klinikai gyakorlat részévé váltak, azonban előrehaladott esetekben ezek a terápiás szerek
Takács, Bettina
core  

Translating whole‐genome doubling into precision medicine in cancer

open access: yesMolecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Circ_0001944 Contributes to Glycolysis and Tumor Growth by Upregulating NFAT5 Through Acting as a Decoy for miR-142-5p in Non-Small Cell Lung Cancer

open access: yesCancer Management and Research, 2021
Yawei Dou,1 Wei Tian,1 Hongtao Wang,1 Shanshan Lv2 1Department of Thoracic Surgery, Shaanxi Province People’s Hospital, Xi’an, 710068, People’s Republic of China; 2Department of Cardiovascular Surgery, Xijing Hospital of Airforce ...
Dou Y, Tian W, Wang H, Lv S
doaj  

Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies

open access: yes, 2015
Lung cancer is the third most commonly diagnosed cancer and the leading cause of cancer-related death in the United States. Unlike non-squamous NSCLC, squamous NSCLC rarely harbor epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase ...
Sarah L Scarpace
core   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

open access: yesMolecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy